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The early diagnosis of active hepatitis C virus (HCV) infection remains a significant barrier to
the treatment of the disease and to preventing the associated significant morbidity and
mortality seen, worldwide. Current testing is delayed due to the high cost, long turnaround
times and high expertise needed in centralised diagnostic laboratories. Here we demonstrate
a user-friendly, low-cost pan-genotypic assay, based upon reverse transcriptase loop medi-
ated isothermal amplification (RT-LAMP). We developed a prototype device for point-of-care
use, comprising a LAMP amplification chamber and lateral flow nucleic acid detection strips,
giving a visually-read, user-friendly result in <40min. The developed assay fulfils the current
guidelines recommended by World Health Organisation and is manufactured at minimal cost
using simple, portable equipment. Further development of the diagnostic test will facilitate
linkage between disease diagnosis and treatment, greatly improving patient care pathways
and reducing loss to follow-up, so assisting in the global elimination strategy.
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Hepatitis C virus (HCV) is a major cause of liver-relatedmortality with 71 million people chronically infectedglobally. Recent advances in direct acting antiviral treat-
ments have improved cure rates to >95%. However, currently an
estimated 80% of all infected individuals are unaware of their
status due to the asymptomatic nature of infection. Many of these
patients will remain undiagnosed until irreversible clinical man-
ifestations, such as liver cirrhosis and hepatocellular carcinoma,
develop, contributing to the 400,000 HCV related deaths reported
every year1.
The World Health Organisation (WHO) has established a
global elimination strategy to reach significant disease reduction
targets by 20302,3. The most challenging obstacle in achieving this
ambitious goal is the rapid diagnosis of patients and their inte-
gration into an appropriate clinical care pathway for treatment3.
Current diagnostic strategies rely on testing for anti-HCV
antibodies followed by RNA or core antigen detection4. This two-
step process requires a centralised laboratory infrastructure and
delays active HCV infection diagnosis by significant periods of
time. Successful implementation is also limited by cost, long
turnaround times and the high level of expertise required for
diagnostic testing. High risk groups, including people-who-inject-
drugs (PWID), are often lost to follow-up due to the multiple
visits required for HCV diagnosis. Additionally, absent or delayed
seroconversion, particularly in immunocompromised patients,
may reduce overall rates of diagnosis5.
Most individuals with HCV reside in low and middle-income
countries (LMICs) with only limited access to diagnosis1,6.
Although recent advances in HCV nucleic acid amplification tests
(NAATs) have provided a possible solution for improving the
management of HCV diagnosis, the existing diagnostic platforms
still pose several limitations, including the high cost and training
requirements associated with polymerase chain reaction (PCR)
assays, especially when used in decentralised testing7,8. Not only
are simpler and cheaper NAATs for point-of-care (POC) testing
required in order to improve HCV diagnosis and eliminate the
need for follow-up visits3, but importantly, the selection of a
universal NAATs’ target is needed. HCV, like many RNA viruses,
exhibits high genetic diversity, with eight distinct HCV genotypes
and at least 90 different subtypes identified with varied prevalence
gobally9,10.
Loop mediated isothermal amplification (LAMP) assays pro-
vide high sensitivity and specificity through the use of 4–6 pri-
mers, which target 6–8 regions within a sequence of interest11,12.
The amplification reaction takes place at a constant temperature
between 60–65 °C, offering a cheaper alternative to the traditional
PCR assays, with minimal equipment requirements, which has
resulted in its use in decentralised (POC) settings to detect the
presence of a variety of pathogens13–15.
Recently, LAMP assays have also been developed for HCV
detection in centralised facilities. Colorimetric outputs have also
been developed to enable the detection without bulky optical
instrumentation with excellent performance for some genotypes
(e.g. Hongjaisee S. et al.16 showed 100% sensitivity with genotype
6). However, these assays showed limited diagnostic performance
when used with varied genotypes or low viral loads17–19. Their
application as POC tests is thus restricted, especially in LMICs20,
where a wide variation in the genetic diversity may lead to a
lower efficacy of tests.
In this study, we now demonstrate a pan-genotypic HCV
LAMP assay, which we validated in a prototype POC diagnostic
device as a paper-microfluidic, visually read lateral flow test. The
assay was validated as part of a double-blind clinical study of
samples from patients with a range of viral loads and genotypes as
determined by a highly sensitive gold-standard Abbott RealTime
RT-PCR HCV test, within a clinical reference laboratory and our
own in-house HCV RT- PCR. We subsequently implemented the
LAMP nucleic acid detection strip method into a portable and
user-friendly device, with an easy-to-use readout for target
detection.
Results
Optimisation of HCV LAMP primers. Previously published
LAMP primers were selected based on evidence of a low limit of
detection from HCV RNA (50 IU/mL)17. In this study, the use of
an additional accelerating primer (AP, Table 1) ensured improved
sensitivity and specificity across several HCV genotypes. We
analysed an alignment file of over 200 sequences of major HCV
genotypes and subtypes21. The majority of the observed mis-
matches were in the middle of the primers (Fig. S1). We only
noted one mismatch within the last base pair of the 3′ end of the
backward loop primer (BLP), within genotype 3 sequences.
Focussing on genotype 3 and in order to further improve the
previously published assay, we removed the cytosine mismatch at
the 3′ end of BLP. Additionally, a cytosine was added at the
beginning of the primer, in order to conserve the primer melting
temperature (Fig. S1 and Table 1). The removal of the cytosine
mismatch and the subsequent use of the new primer improved
the time to positivity by 21% in genotype 3 (Fig. S2). As a con-
firmation, the new BLP was also compared to the original BLP
performance on genotype 1 targets, which, did not result in sig-
nificant differences in the assay performance as there were no
mismatches within this genotype.
Clinical sensitivity and specificity. Using optimised primers, we
conducted a double-blind study of LAMP on RNA and cDNA
from samples with a range of viral loads and from different HCV
genotypes, including a recently identified genotype 7a (Table 2)22.
The performance of HCV LAMP using RNA samples (RT-
LAMP) directly and HCV LAMP using cDNA as template were
compared with a highly sensitive in-house HCV RT- PCR by
genotype and viral load (Tables 2 and 3). The in-house RT-PCR
assay has been characterised previously as a quantitative assay
(qRT-PCR23).
HCV RT-LAMP and HCV LAMP assays detected 96 and 97
HCV samples out of 100 respectively, comparable with the RT-
PCR assay which detected 96/100 samples. The false negatives
correlated well between the three assays (in two cases false
negatives were due to low viral loads, ≤3.95 log10 IU/mL). RT-
LAMP failed to detect a single genotype 4 sample with high viral
load (5.64 log10 IU/mL). RT-LAMP and LAMP assays both
exhibited high specificity, correctly identifying 91 and 90 control
Table 1 LAMP primer sequences.
Primer name Sequence (5′ → 3′)
F3 ACT CCA CCA TGA ATC ACT C
B3 ATC AGG CAG TAC CAC AAG G
FIP AGG CTG YAC GAC ACT CAT AC-CTG
TGA GGA ACT ACT GTC TTC
BIP GGA TMA ACC CRC TCA ATG CC-TCG
CRA CCC AAC RCT AC
FLP GCC ATG GCT AGA CGC T
BLP CGT GCC CCC GCR AGA[C]
AP TTC CGC AGA CCA CTA TGG CTC T
FLP BIO [BIO] GCC ATG GCT AGA CGC T
BLP FITC [FITC] CGT GCC CCC GCR AGA
Primer sequences were as published by Yang et al.17, with modifications marked in bold,
underlined. The bracket shows the original cytosine position.
FIP forward internal primer, BIP backward internal primer, FLP forward loop primer, BLP backward
loop primer, AP accelerating primer, Bio Biotin, FITC fluorescein isothiocyanate.
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samples out of 100 respectively, although our in-house RT-PCR
assay had a higher specificity with no false positives.
Time to detection. In order to evaluate the impact of genotype
and viral load on the performance of both HCV RT-LAMP and
LAMP assay, we defined samples as positive when the fluores-
cence signal was at least ten standard deviations above the mean
baseline fluorescence of the positive control. The time to positive
was then determined as described in Fig. S3. The majority of
positive samples were detected within 30 min (Fig. 1a, b). For RT-
LAMP, genotype 3 and 4 detection took longer than genotype 1
and 2. Similarly, for cDNA, genotype 3 positivity occurred later
than all other genotypes. There was an inverse relationship
between time to detection and viral load and significant differ-
ences occurred between the 1.70–3.95 log10 IU/mL group,
4.40–4.85 log10 IU/mL group and the 6.05–6.97 log10 IU/mL
group for both RNA and cDNA (Fig. 1c, d).
Since most samples were detected within the first 30 min, we
assessed if this would be a suitable detection time period. Receiver
operating characteristic (ROC) curves for both LAMP and the
RT-PCR were used to determine the efficacy by which the assays
would distinguish between HCV-positive and control samples at
different time points or cycles (Fig. 2, Fig. S4 and Tables S1–2).
Both RT-LAMP and LAMP had areas under the curve of 0.97
(Fig. 2A, B), showing close statistical similarity to the RT-PCR
assay (Fig. S4 and Table S1). The cut-off of <29 min for RT-
LAMP was equivalent to 95.0% sensitivity (95% CI: 88.7–98.4%)
and 94.0% specificity (95% CI: 87.4%–97.8%) (Fig. 2C and
Table S2). LAMP had the same sensitivity at <29.75 min, but the
specificity was slightly lower—92.0% (95% CI: 84.8–96.5%)
(Fig. 2D and Table S3). To achieve the specificity of 98%,
recommended by the WHO, (98.0%, 95% CI of 93.0–99.8%), the
cut-off value would be set to <24.75 min for RT-LAMP and
<26.75 min for LAMP, resulting in a sensitivity of 90.0% (95% CI
of 82.4–95.1%) and 92.0% (95% CI of 84.8–96.5%) for RT-LAMP
and LAMP, respectively (Fig. 2C, D, Tables S1–3)24.
Analytical sensitivity and end-point detection. Analytical sen-
sitivity of HCV LAMP was assessed using serial dilutions of
plasmids containing HCV sub-genomic replicon over 40 min by
three different detection methods; nucleic acid detection strips,
gel electrophoresis and changes in fluorescence over time. The
concentration of HCV ranged between 2.6 log10 copies/reaction
and 4.1 log10 copies/reaction. Figure 3 shows the mechanism of
strip detection (Fig. 3a), the assembly of the lateral flow device
(Fig. 3b), and the results from the analytical sensitivity experi-
ments (Fig. 3c). The lower limit of detection was the same for
each method, below 2.6 log10 copies/reaction (broadly equivalent
to a detection threshold of 398 copies/reaction, which is lower
than the recommended ≤3000 IU/mL limit of detection by
WHO)2.
The nucleic acid detection strips used in this study offered an
easy-to-interpret pregnancy test-like result with two bands for a
positive reaction and one (control) band for negative. The gel
electrophoresis revealed a characteristic smear with ladder-like
banding pattern for all samples except the negative control. The
size of the initial bands (274 bp) correlate with the region between
F3/B3 representing the initial stem loop formation of the reaction.
As the reaction proceeded, larger constructs were created, with
random termination, generating a other bands with a smear-like
pattern11,12,17. The results correlated with the nucleic acid
detection strips. There was an inverse relationship between viral
load and time to positivity and all positive reactions were
statistically different from the negative control (p < 0.0001). The
double-blind study revealed that optimal sensitivity and specificity
occur at <30min with a lower limit of detection of 417 IU/mL.
Nucleic acid detection strips are easy to visualise and interpret
and are known to correlate well with other detection methods and
were thus used as the basis for the development of a low-cost,
microfluidic HCV test, which could be used either in bedside and/
or POC settings. An enclosed lateral flow device containing a
LAMP reaction chamber, valves and detection strips was
manufactured in-house using methods adapted from previous
studies (shown in Fig. 3b and Fig. S5)15. The LAMP chamber was
incubated in a heat block for 30 min at 65 °C by inserting the
device upright (thus ensuring that the lateral flow strips were held
away from high temperatures, Fig. S6). At the end of the reaction,
the amplicons, generated within the LAMP chamber were eluted
onto the lateral flow strips by pressing a blister pack/finger pump
containing running buffer. The amplicons, labelled with both
FITC and biotin ligand binding sites, contacted the end of the
lateral flow devices and then were carried along the paper strips
by capillarity, where they interacted with conjugation pads. This
prototype HCV test device offers a cheap and user-friendly
detection method together with the high sensitivity and specificity
of the LAMP reaction.
To characterise the performance of the lateral flow detection
devices, we tested a further 40 patient samples (20 HCV-positive
and 20 healthy controls) on this platform and compared the
results to our in-house qPCR assay (see ‘Methods’ for details).
Results show no false positives (20/20 negatives detected correctly,
Supplementary Table S4). Three clinically positive samples did not
provide any Ct value on qPCR, indicative of either or both of
low viral loads or degradation of the RNA from the additional
Table 2 Sample detection by genotype and viral load.
Genotype RT-LAMP LAMP RT-PCR Total samples
tested (%)
1 25 25 25 26 (26%)
2 14 14 14 14 (14%)
3 22 22 21 23 (23%)
4 21 22 22 22 (22%)
5 3 3 3 3 (3%)
6 1 1 1 1 (1%)
7 1 1 1 1 (1%)




1.7–3.95 3 3 2 5 (5%)
4.4–4.85 12 12 12 12 (12%)
5.2–5.98 36 37 37 37 (37%)
6.05–6.97 37 37 37 37 (37%)
Unknown 8 8 8 9 (9%)
Total 100
Experiments were performed in duplicate and at least one positive replicate was interpreted as a
positive result.
Table 3 Sensitivity and specificity of HCV assays.
Method RT-LAMP LAMP RT-PCR
True positive 96 97 96
False negative 4 3 4
Total (sensitivity) 100 (96%) 100 (97%) 100 (96%)
True negative 91 90 100
False positive 9 10 0
Total (specificity) 100 (91%) 100 (90%) 100 (100%)
Abbott RealTime HCV assay (RT-PCR) was used as the gold standard.
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freeze-thaw cycles and longer storage. 14/17 positive samples were
also identified correctly by the LAMP on lateral flow devices. Two
of the false negative samples had Ct values above 30 for our in
house qPCR, which is beyond our threshold for detection,
indicating low viral loads. Consequently, only one sample (Ct
29) was negative for the lateral flow device, whilst being positive
for qPCR, showing excellent agreement, in line with the results
obtained for fluorescence read-outs and demonstrating the
potential for this low-cost and user-friendly method.
Discussion
In this study, we aimed to develop a cheap, sensitive and specific
bedside test for HCV. Using optimised primers, we validated its
potential as a future POC/bedside test in a double-blind study of
clinical samples with varied viral loads and comprising all major
genotypes, including a recently identified genotype 7 sample22.
Both RT-LAMP and LAMP performed well in this study,
exceeding the standards set out by WHO for POC tests24. The
samples were diagnosed by comparison with the gold standard
Abbott RealTime HCV PCR assay within a validated clinical
reference laboratory and further compared with an in-house RT-
PCR assay. A small number of samples that were not detected by
RT-PCR were also missed by the LAMP assay, possibly due to low
viral load.
The target product profile for diagnosis of HCV as recom-
mended by WHO requires a minimum diagnostic specificity



































































































Fig. 1 The effect of genotype and viral load on detection. The central lines indicate median with interquartile range as error bars, and each point on the
graph represents the mean of a sample run in duplicate. False negative samples were recorded as time to positive reaction at 45min. Statistical analysis
was performed using a one-sided non-parametric Kruskal-Wallis with Dunn’s multiple comparisons test (one-sided). *p≤ 0.05, **p≤ 0.01, ***p≤ 0.001,
****p≤ 0.0001. a HCV RNA samples detection based on genotype (Gt): Gt1 (grey square, n= 26), Gt2 (white and black disc, n= 14), Gt3 (grey triangle,
n= 23), Gt4 (grey lozenge, n= 22), Gt5 (black disc, n= 3), Unknown (grey inverse triangle, n= 10). Gt1 vs Gt3, p < 0.0001, Gt1 vs Gt4, p < 0.0001, Gt1 vs
Unknown, p= 0.1524, Gt2 vs Gt3, p= 0.0101, Gt2 vs Gt4, p= 0.0284, Gt3 vs Gt5, p= 0.1846, Gt4 vs Gt5, p= 0.2814. All remaining groups had p values
of >0.9999. b HCV cDNA samples detection based on genotype; Gt1 (grey square, n= 26), Gt2 (white and black disc, n= 14), Gt3 (grey triangle, n= 23),
Gt4 (grey lozenge, n= 22), Gt5 (black disc, n= 3), Unknown (grey inverse triangle, n= 10). Gt1 vs Gt3, p < 0.0001, Gt1 vs Gt4, p= 0.0562, Gt1 vs
Unknown, p= 0.3425, Gt2 vs Gt3, p= 0.0002, Gt3 vs Gt4, p= 0.0490, Gt3 vs Gt5, p= 0.0035, Gt3 vs Unknown, p= 0.3247, Gt4 vs Gt5, p= 0.3701, Gt5
vs Unknown, p= 0.5210. All the remaining groups had p values of >0.9999. c HCV RNA samples detection based on viral load: 1.7–3.95 (grey square,
n= 5), 4.4–4.85 (black and white disc, n= 11), 5.2–5.98 (grey triangle, n= 34), 6.05–6.97 (grey lozenge, n= 44). 1.7–3.95 vs 5.2–5.98, p= 0.1937,
1.7–3.95 vs 6.05–6.97, p= 0.0095, 4.4–4.85 vs 6.05–6.97, p= 0.0301, 5.2–5.98 vs 6.05–6.97, p= 0.4768, 5.2–5.98 vs Unknown, p= 0.4506, 6.05–6.97
vs Unknown, p= 0.0118. All remaining groups had p values of >0.9999. d HCV cDNA samples detection based on viral load; 1.7–3.95 (grey square, n= 5),
4.4–4.85 (black and white disc, n= 11), 5.2–5.98 (grey triangle, n= 34), 6.05–6.97 (grey lozenge, n= 44). 1.7–3.95 vs 5.2–5.98, p= 0.0536, 1.7–3.95 vs
6.05–6.97, p= 0.0032, 1.7–3.95 vs Unknown, p= 0.5693, 4.4–4.85 vs 6.05–6.97, p= 0.0492, 5.2–5.98 vs 6.05–6.97, p= 0.9431, 6.05–6.97 vs Unknown,
p= 0.7858. All remaining groups had p values of >0.9999. Source data are provided as a Source data file.
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RT-LAMP at a cut-off of <25 min22. However, the optimal ana-
lytical sensitivity of RT-LAMP assay, exceeding the WHO
requirements, was reached at a cut-off of <30 min. The small
number of false positive samples detected by LAMP versus RT-
PCR could represent a slightly increased risk of cross-
contamination or the formation of primer-dimer structures
detected by LAMP. Overall, false positives did not occur com-
monly in this study, as in other HCV LAMP studies17–19,25.
The analytical sensitivity of the assay at 40 min was ~2.6 log10
copies/reaction. In the original study from which we adapted our
primers, the authors report a limit of detection of 50 IU/mL17.
Both studies show that the assay falls well within the WHO’s
criteria for a point-of-care test (3000 IU/mL or below)2.
The current diagnostic algorithm for HCV relies on testing
for anti-HCV antibodies and later for HCV RNA to confirm
active infection1. Although, rapid diagnostic tests for anti-HCV
antibody detection have been developed and FDA approved,
they are still limited by the window period in early HCV
infection when antibodies are undetectable26. Detection of
current infection has to be confirmed by highly sensitive and
specific HCV RNA detection assays including RT-PCR
and those are still primarily limited by the high costs
involved and incur a significant delay for patient management,
which can be associated with poor treatment initiation
outcomes27. The recent development of platforms such as
GeneDrive and Cepheid Xpert, which are both CE-IVD certi-
fied, have improved the HCV diagnostic landscape with very
high sensitivity and specificity, but require technical expertise
and significant financial investment7,8. Both assays need a
trained laboratory technician with at least one day of training to
perform the assay. Furthermore, the cost of the GeneDrive
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Fig. 2 ROC curves for LAMP assays. ROC curves were based on mean time to detection of 100 HCV positive and 100 HCV negative samples tested in a
double-blind fashion. A, B ROC curve analysis, performed using the Clopper-Pearson Method (one-sided, no adjustments for multiple comparisons) for RT-
LAMP and RNA samples (a) and for LAMP and cDNA samples (B). C, D Graphs showing sensitivity (circle) and specificity (triangle) at different time
points in minutes for RT-LAMP (C) and LAMP (D). Error bars are 95% confidence intervals. The dashed line indicates the cut-off time in minutes, where
sensitivity and specificity is optimal. Source data are provided as a Source data file.
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comparison, the authors of this study have previously estimated
the cost of a similar LAMP assay to be < $1015.
The prototype lateral flow device developed in this study does
not affect the sensitivity of the assay when compared to gel
electrophoresis and fluorescence-based detection. Nucleic acid
detection was carried out with an easy-to-interpret, pregnancy
test-like visualisation output, requiring two labelled primers
(Fluorescein isothiocyanate, FITC, labelled FLP and biotin, Bio,
labelled BLP) specific to double-stranded HCV LAMP amplicons.
Compared to our previous study15, which focussed on the
detection of plasmodium DNA, we demonstrate this capability
with the amplification of RNA for the detection of HCV. This
contrasts with previous HCV LAMP studies that have used SYBR
green for colorimetric detection with non-specific detection of
double-stranded DNA, which may result in higher numbers of
false positive results19.
In future work, we propose to integrate an RNA extraction
system within the current lateral flow device. Candidate systems
have already been described and have used LAMP directly from
serum, urine and whole blood, for example in Zika virus detec-
tion, without significantly impairing assay performance28–30.
Other studies have reported the use of paper microfluidics as a
suitable RNA extraction method in conjugation with LAMP
reactions including a recently published 30-second nucleic acid
extraction protocol31,32. The incorporation of such methods with
our highly sensitive and specific HCV LAMP assay would allow
for a sample-to-answer test result within 60 min. A single visit
would then be sufficient for diagnosis and initiation of treatment
which could significantly improve the uptake of treatment in high
risk groups including PWID and HIV infected men-who-have-
sex-with-men by reducing loss to follow-up33,34. PWID have a
high global prevalence of HCV infection with an estimated 10
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Fig. 3 Lateral flow detection of HCV LAMP assay. a The mechanism of the lateral flow strip15. Two primers, FLP and BLP, are pre-labelled with Biotin and
FITC, respectively. The amplicon resulting from the LAMP reaction, contains both labelled primers as double-stranded DNA represented schematically by
two gray lines. It is added onto the sample pad and moves towards the conjugate via capillary action. The streptavidin-labelled red particles bind with the
Biotin (from the FLP primer) on the amplicon and together move towards the test line. The anti-FITC antibody (Ab) on the strip captures the amplicon via
its FITC label (from the BLP primer) at the test line forming a band. Any unbound red particles move towards the control line where they are captured via
the Biotin forming a second band. b The assembly and interpretation of the lateral flow devices. The device consists of the water chamber (1), connecting
channels (2), four LAMP reaction chambers (3), channels (4) and lateral flow strips (5). Following the incubation period, two bands indicate a positive
reaction, one band indicates a negative and no bands indicate invalid results. P—positive, N—negative, 1 and 2—sample in duplicate. c Analytical sensitivity
of the lateral flow method (top panel) compared to gel electrophoresis (middle panel) and fluorescence over time (bottom panel). Serial dilutions of
plasmid JFH1 replicon were made based on copy number per reaction (log10). Black lines indicate median with interquartile range (n= 3 biologically
independent experiments, each with three technical replicates). The different symbols are for each dilution, to ease visualisation (grey and white disc—4.1,
white lozenges—3.8, inverse triangles—3.5, black diamond—3.2, grey circles—2.9 and white squares—2.6 log10 copies/reaction, black disc is negative
control—DI water). Statistical analysis for the fluorescence over time was performed using a parametric, one-way ANOVA. The F ratio= 55.56 and the
degrees of freedom= 65. ****p≤ 0.0001, Pos—positive HCV control, Neg—no template control, M—100 bp NEB DNA ladder, C—control line, T—test line.
Source data are provided as a Source data file.
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million positive for anti-HCV antibodies in 148 countries34,35.
Several studies have demonstrated that POC testing is cost-
effective in high-risk groups as well as in countries with high
HCV prevalence such as Egypt36,37. Since LAMP requires a stable
temperature of 60–65 °C with no cycling, reactions can be
established with minimal equipment requirements, for example
by using a commercially available thermos flask, water bath or
coffee mug38. Using such methods, LAMP performs well in the
field for the diagnosis of malaria15 and foot-and-mouth disease14
amongst others.
HCV LAMP is suitable for diagnosis across a range of different
viral loads and genotypes. Differences were noted in the time to
detection of genotype 3 with the LAMP assay and genotypes 3
and 4 for RT-LAMP, although these were significantly improved
by the alteration of the BLP primer in optimisation experiments
and were detected in <30 min. Assay performance could be
optimised further by altering primer sequences based on the
genotypes most prevalent in the area in which diagnosis is
taking place.
In conclusion, we have developed a highly sensitive and specific
HCV LAMP assay, which exceeds WHO requirements for a
diagnostic test. Our prototype lateral flow device is a promising
tool for user-friendly POC testing, eliminating the need for follow
up visits between diagnosis and initiation of treatment. Future
studies should evaluate prospective testing in the field in patients
receiving HCV treatment.
Methods
Clinical samples and standards. 100 fully anonymised plasma samples from
patients with chronic HCV infection were compared with 100 HCV-negative
control samples. Samples, including healthy controls, were selected randomly from
the West of Scotland Specialist Virology Centre (WoSSVC) via the Greater Glas-
gow and Clyde Health Bio-repository and the NHS Research Ethics Committee
(REC), anonymised and processed from plasma at the MRC, Centre for Virus
Research or from venous whole blood at the WoSSVC, Glasgow Royal Infirmary.
Ethical approval was granted by the Greater Glasgow and Clyde Health Bio-
repository and the NHS Research Ethics Committee, application number 606. All
samples were obtained with informed consent, with no compensation. Samples
were assigned a numerical sample ID (1–200 or 1–40) randomly (using the random
number generator in Microsoft Excel 365) and processed from venous whole blood
at the WoSSVC. The correspondence (positive, negative and viral load when
relevant) was held by the WoSSVC. The samples were provided blinded for
processing.
The HCV viral load was quantified using the Abbott RealTime HCV assay. The
viral load groupings were defined by the WoSSVC according to common clinical
practice. Sensitivity and specificity testing was carried out using a double-blind
study design. Analytical sensitivity was determined by serial two-fold dilutions of
JFH1 subgenomic replicon containing the Guassia luciferase gene (pSGR-HCV-
JFH1-GLUC)39. The number of copies of replicon per reaction was calculated
based on DNA mass and plasmid length on the NEB online calculator40.
40 samples stored at −80 °C, from patients with HCV (n= 20) and negative
controls (n= 20) were anonymised by WoSSVC staff. They were transported to the
University of Glasgow on ice and stored at −80 °C until use. They were processed
according to the procedure detailed below for the LAMP lateral flow devices and
RT-PCR, in a double-blind fashion. The results were read independently by two
assessors before unblinding.
RNA extraction and cDNA synthesis. RNA was extracted from 200 µL of plasma
using the Agencourt RNAdvance Blood Kit (Beckman Coulter) on the automated
KingFisher™ Flex Purification System, with a method adapted from the manu-
facturer’s protocol. Samples were lysed with 300 µL of Lysis buffer and 30 µL of
Proteinase K and the DNase stage was shortened to 5 min. Purified RNA was eluted
in 25 µL of nuclease-free water. SuperScript III Reverse Transcriptase (Thermo
Fisher Scientific) was used for complementary DNA synthesis from 11 µL of eluted
RNA with random hexamers as per the manufacturer’s instructions.
HCV LAMP assay and product detection. LAMP reactions were run in a final
volume of 25 µL, containing 15 µL of ISO-001-RT Master Mix (Optigene, UK),
5 µL of target DNA/RNA, 0.8 µM of FIP and BIP, 0.4 µM of FLP and BLP, 0.2 µM
of F3 and B3 primers and 0.4 µM of AP. Primer sequences are shown in Table 1.
Reaction mixtures were incubated for 40–45 min at 65 °C. Real time monitoring
of LAMP reactions was performed on a 7500 Fast Real-Time PCR (RT-PCR)
machine (Applied Biosystems) using the SYBR green setting. For end-point
detection, LAMP products were subjected to gel electrophoresis on a 1% agarose
TAE gel dyed with ethidium bromide and the results detected under UV light.
Additionally, LAMP products were visualised on nucleic acid detection strips
(Ustar®, China). FLP and BLP were labelled with Biotin and FITC, respectively
(Table 1), and the entire product was added to the strips and topped up with
~100 µL of nuclease free deionised water to enable the flow of the sample through
the lateral strip using capillarity. The results were recorded within 10 min by the
ESPON EXPRESSION 1680 Pro scanner with 300 dpi resolution. Images were
processed in Microsoft PowerPoint 2016 software.
Lateral flow devices. Lateral flow devices containing chambers for LAMP reactions,
finger pumps and nucleic acid detection strips were manufactured in-house on a laser
cutter (Laserscript) from 2 mm-thick poly(methylmethacrylate) (Fig. 3b and Fig. S5a).
Two single sided adhesive acetate films (MicroAmp Optical Adhesive Film; Thermo
Scientific) were used to seal the devices and prevent evaporation during LAMP
reactions. These devices are low-cost, estimated as follows: cartridge < $10c, detection
strip $1, reagents (3 reactions (positive, negative, test)), $3. Total < $5.
HCV RT-PCR assay. An in-house RT-PCR with primer and probe sequences
based on the 5′UTR (JFH1- primer 16; 5′-TCTGCGGAACCGGTGAGTAC-3′,
JFH1-primer 17; 5′-GCACTCGCAAGCACCCTAT-3′, FAM probe; 6-FAM-
AAAGGCCTTGTGGTACTG-MGB) was used for comparison, whilst the Abbott
real-time RT-PCR assay was used as a gold-standard HCV detection reference
assay. Each master mix consisted of 2× TaqMan Fast Universal Mix (Thermo
Fisher Scientific), 18 µM forward and reverse primers, 5 µM probe and 1 µL cDNA
template in a final volume of 10 µL. The run consisted of 20 s hold at 95 °C
followed by 40 cycles of denaturation for 20 s at 95 °C and amplification for 30 s
at 60 °C.
Statistical analysis. Normal distribution of data was determined in GraphPad
Prism version 7 using D’Agostino & Person normality test. A parametric one-way
ANOVA was used for normally distributed data and a non-parametric Kruskal-
Wallis test with Dunn’s multiple comparisons test was used for other data types.
ROC curves were plotted on the same software. Data were considered significant if
p value was less than or equal to 0.05.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The raw data, sequence alignment, gel blots and images that support the findings of this
study are also available in University of Glasgow’s Enlighten: Research Data with the
identifier: https://doi.org/10.5525/gla.researchdata.1127. Source data are provided with
this paper.
Received: 29 March 2021; Accepted: 27 October 2021;
References
1. European Association for the Study of the Liver. EASL Clinical Practice
Guidelines: Management of hepatitis C virus infection. J. Hepatol. 60, 392–420
(2014).
2. World Health Organization. Guidelines for the Screening Care and Treatment
of Persons with Chronic Hepatitis C Infection: Updated Version (World Health
Organization, 2016).
3. Chevaliez, S. & Pawlotsky, J.-M. Hepatitis C virus serologic and virologic tests
and clinical diagnosis of HCV-related liver disease. Int J. Med Sci. 3, 35–40
(2006).
4. Iversen, J. et al. Estimating the Consensus hepatitis C Cascade of Care among
people who inject drugs in Australia: pre and post availability of direct acting
antiviral therapy. Int. J. Drug Policy 83, 102837 (2020).
5. Thomson, E. C. et al. Delayed anti-HCV antibody response in HIV-positive
men acutely infected with HCV. AIDS 23, 89–93 (2009).
6. Gower, E., Estes, C., Blach, S., Razavi-Shearer, K. & Razavi, H. Global
epidemiology and genotype distribution of the hepatitis C virus infection. J.
Hepatol. 61, S45–S57 (2014).
7. Lamoury, F. M. J. et al. Evaluation of the Xpert HCV viral load finger-stick
point-of-care assay. J. Infect. Dis. 217, 1889–1896 (2018).
8. Llibre, A. et al. Development and clinical validation of the Genedrive point-of-
care test for qualitative detection of hepatitis C virus. Gut 67, 2017–2024 (2018).
9. Walker, P. J. et al. Changes to virus taxonomy and the statutes ratified by the
international committee on taxonomy of viruses (2020). Arch. Virol. 165,
2737–2748 (2020).
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-27076-z ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:6994 | https://doi.org/10.1038/s41467-021-27076-z | www.nature.com/naturecommunications 7
10. Borgia, S. M. et al. Identification of a novel hepatitis C virus genotype from
punjab, india: expanding classification of hepatitis C virus into 8 genotypes. J.
Infect. Dis. 218, 1722–1729 (2018).
11. Notomi, T. et al. Loop-mediated isothermal amplification of DNA. Nucleic
Acids Res. 28, e63–e63 (2000).
12. Nagamine, K., Hase, T. & Notomi, T. Accelerated reaction by loop-mediated
isothermal amplification using loop primers. Mol. Cell. Probes 16, 223–229
(2002).
13. Viana, G. M. R. et al. Field evaluation of a real time loop-mediated isothermal
amplification assay (RealAmp) for malaria diagnosis in Cruzeiro do Sul, Acre,
Brazil. PLoS ONE 13, e0200492 (2018).
14. Howson, E. L. A. et al. Evaluation of two lyophilized molecular assays to
rapidly detect foot-and-mouth disease virus directly from clinical samples in
field settings. Transbound. Emerg. Dis. 64, 861–871 (2017).
15. Reboud, J. et al. Paper-based microfluidics for DNA diagnostics of malaria
in low resource underserved rural communities. PNAS 116, 4834–4842
(2019).
16. Hongjaisee, S. et al. Rapid visual detection of hepatitis C virus using a reverse
transcription loop-mediated isothermal amplification assay. Int. J. Infect. Dis.
102, 440–445 (2021).
17. Yang, J. et al. Detection of hepatitis C virus by an improved loop-mediated
isothermal amplification assay. Arch. Virol. 156, 1387–1396 (2011).
18. Kargar, M., Askari, A., Doosti, A. & Ghorbani-Dalini, S. Loop-mediated
isothermal amplification assay for rapid detection of hepatitis C virus. Indian
J. Virol. 23, 18–23 (2012).
19. Wang, Q. et al. Rapid detection of hepatitis C virus RNA by a reverse
transcription loop-mediated isothermal amplification assay. FEMS Immunol.
Med. Microbiol. 63, 144–147 (2011).
20. Schnell, G. et al. Hepatitis C virus genetic diversity by geographic region
within genotype 1–6 subtypes among patients treated with glecaprevir and
pibrentasvir. PLoS ONE 13, e0205186 (2018).
21. Smith, D. B. et al. Expanded classification of hepatitis C virus into 7 genotypes
and 67 subtypes: Updated criteria and genotype assignment web resource.
Hepatology 59, 318–327 (2014).
22. Davis, C. et al. Highly diverse hepatitis C strains detected in sub-saharan africa
have unknown susceptibility to direct-acting antiviral treatments. Hepatology
69, 1426–1441 (2019).
23. Witteveldt, J. et al. CD81 is dispensable for hepatitis C virus cell-to-cell
transmission in hepatoma cells. J. Gen. Virol. 90, 48–58 (2009).
24. Ivanova Reipold, E. et al. Optimising diagnosis of viraemic hepatitis C
infection: the development of a target product profile. BMC Infect. Dis. 17, 707
(2017).
25. Nyan, D.-C. & Swinson, K. L. A method for rapid detection and genotype
identification of hepatitis C virus 1–6 by one-step reverse transcription loop-
mediated isothermal amplification. Int. J. Infect. Dis. 43, 30–36 (2016).
26. Lee, S. R. et al. Evaluation of a new, rapid test for detecting HCV infection,
suitable for use with blood or oral fluid. J. Virol. Methods 172, 27–31 (2011).
27. Busch, M. P. Insights into the epidemiology, natural history and pathogenesis
of hepatitis C virus infection from studies of infected donors and blood
product recipients. Transfus. Clin. Biol. 8, 200–206 (2001).
28. Lamb, L. E. et al. Rapid detection of Zika virus in urine samples and infected
mosquitos by reverse transcription-loop-mediated isothermal amplification.
Sci. Rep. 8, 3803 (2018).
29. Damhorst, G. L. et al. Smartphone-imaged HIV-1 reverse-transcription loop-
mediated isothermal amplification (RT-LAMP) on a chip from whole blood.
Engineering 1, 324–335 (2015).
30. Ihira, M. et al. Direct detection of human herpesvirus 6 DNA in serum by the
loop-mediated isothermal amplification method. J. Clin. Virol. 39, 22–26
(2007).
31. Zou, Y. et al. Nucleic acid purification from plants, animals and microbes in
under 30 s. PLoS Biol. 15, e2003916 (2017).
32. Kaarj, K., Akarapipad, P. & Yoon, J.-Y. Simpler, faster, and sensitive Zika virus
assay using smartphone detection of loop-mediated Isothermal amplification
on paper microfluidic chips. Sci. Rep. 8, 12438 (2018).
33. Linas, B. P., Wong, A. Y., Schackman, B. R., Kim, A. Y. & Freedberg, K. A.
Cost-effective screening for acute hepatitis C virus infection in HIV-infected
men who have sex with men. Clin. Infect. Dis. 55, 279–290 (2012).
34. Martin, N. K. et al. Can antiviral therapy for hepatitis C reduce the prevalence
of HCV among injecting drug user populations? A modeling analysis of its
prevention utility. J. Hepatol. 54, 1137–1144 (2011).
35. Nelson, P. K. et al. Global epidemiology of hepatitis B and hepatitis C in
people who inject drugs: results of systematic reviews. Lancet 378, 571–583
(2011).
36. Schackman, B. R. et al. Cost-effectiveness of rapid hepatitis C virus (HCV)
testing and simultaneous rapid HCV and HIV testing in substance abuse
treatment programs. Addiction 110, 129–143 (2015).
37. Kim, D. D. et al. Cost-effectiveness model for hepatitis C screening and
treatment: implications for Egypt and other countries with high prevalence.
Glob. Public Health 10, 296–317 (2015).
38. Jiang, X., Loeb, J. C., Manzanas, C., Lednicky, J. A. & Fan, Z. H. Valve-enabled
sample preparation and RNA amplification in a coffee mug for Zika virus
detection. Angew. Chem. Int. Ed. 57, 17211–17214 (2018).
39. Domingues, P., Bamford, C. G. G., Boutell, C. & McLauchlan, J. Inhibition of
hepatitis C virus RNA replication by ISG15 does not require its conjugation to




The authors would like to Dr. Shantimoy Kar and Dr. Xiaoxiang Yan from the James
Watt School of Engineering at the University of Glasgow for their inputs on the design of
the lateral flow device. This study was funded in part by Engineering and Physical
Sciences Research Council, Grant Number: EP/M508056/1, Medical Research Council
Grant Numbers: G0801566, G0901213–92157, MC_PC_16045, MC_UU_12014/1, MR/
K013491/1 and the Wellcome Trust, Grant Number: 102789/Z/13/A. We also
acknowledge the support of NHS Research Scotland (NRS) Greater Glasgow and Clyde
Biorepository.
Author contributions
E.C.T., J.M.C. and J.R. supervised the project. A.B.S. determined the viral loads and
genotypes of the HCV samples by the Abbott RealTime PCR. A.B.S. and R.G. provided
and anonymised the samples for the double-blind studies. C.D. and S.R.S. extracted RNA
and conducted cDNA synthesis of all samples for the double-blind study. W.M.W.
performed the LAMP and in-house RT-PCR assays for the double-blind studies.
W.W.M., A.G., G.X. and Z.Y. designed the lateral flow devices. W.W.M. and A.G.
manufactured and assembled the lateral flow devices. W.W.M., P.J., J.M.C. and J.R.
analysed the data. W.W.M. wrote the original manuscript. E.C.T., J.M.C. and J.R. pro-
vided revisions and all authors reviewed and edited the manuscript.
Competing interests
The authors declare no competing interests.
Additional information
Supplementary information The online version contains supplementary material
available at https://doi.org/10.1038/s41467-021-27076-z.
Correspondence and requests for materials should be addressed to Emma C. Thomson
or Jonathan M. Cooper.
Peer review information Nature Communications thanks Maria-Nefeli Tsaloglou and
the other, anonymous, reviewer(s) for their contribution to the peer review of this work.
Peer reviewer reports are available.
Reprints and permission information is available at http://www.nature.com/reprints
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Open Access This article is licensed under a Creative Commons
Attribution 4.0 International License, which permits use, sharing,
adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative
Commons license, and indicate if changes were made. The images or other third party
material in this article are included in the article’s Creative Commons license, unless
indicated otherwise in a credit line to the material. If material is not included in the
article’s Creative Commons license and your intended use is not permitted by statutory
regulation or exceeds the permitted use, you will need to obtain permission directly from
the copyright holder. To view a copy of this license, visit http://creativecommons.org/
licenses/by/4.0/.
© The Author(s) 2021
ARTICLE NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-27076-z
8 NATURE COMMUNICATIONS |         (2021) 12:6994 | https://doi.org/10.1038/s41467-021-27076-z | www.nature.com/naturecommunications
